{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T10:21:29Z","timestamp":1771064489976,"version":"3.50.1"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T00:00:00Z","timestamp":1683072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>COVID-19 inactivated vaccine-induced humoral responses in patients with lung cancer (LCs) to SARS-CoV-2 wild-type (WT) strain and variants BA.4\/5 after the primary 2-dose and booster vaccination remained unknown. We conducted a cross-sectional study in 260 LCs, 140 healthy controls (HC) and additional 40 LCs with serial samples by detecting total antibodies, IgG anti-RBD and neutralizing antibodies (NAb) toward WT and BA.4\/5. SARS-CoV-2-specific antibody responses were augmented by the booster dose of inactivated vaccines in LCs, whereas they were lower than that in HCs. Enhanced humoral responses waned over time after triple injection, notably in NAb against WT and BA.4\/5. The NAb against BA.4\/5 was much lower than WT. Age\u2009\u2265\u200965 was risk factor for immunization of NAb to WT. Undergoing treatment resulted in a lower antibody response than those without and radiotherapy was a also risk factor for seroconversion of NAb to WT. Lower lymphocyte counts contributed to a lower titer of IgG anti-RBD and NAb against BA.4\/5 in LCs than HCs. Specifically, total B cells, CD4<jats:sup>+<\/jats:sup>T cells and CD8<jats:sup>+<\/jats:sup>T counts were correlated with the humoral response. These results should be taken into consideration for the elderly patients under treatment.<\/jats:p>","DOI":"10.1186\/s13045-023-01443-3","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T12:02:27Z","timestamp":1683115347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Antibody response to SARS-CoV-2 WT and Omicron BA.4\/5 of inactivated COVID-19 vaccine in patients with lung cancer after second and booster immunization"],"prefix":"10.1186","volume":"16","author":[{"given":"Chen","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyuan","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cuiling","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haolong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengwei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruyun","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiarui","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhishang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohong","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,3]]},"reference":[{"key":"1443_CR1","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jtho.2021.11.001","volume":"17","author":"C Rolfo","year":"2022","unstructured":"Rolfo C, Meshulami N, Russo A, et al. Lung cancer and severe acute respiratory syndrome coronavirus 2 infection: identifying important knowledge gaps for investigation. J Thorac Oncol. 2022;17:214\u201327.","journal-title":"J Thorac Oncol"},{"key":"1443_CR2","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","volume":"596","author":"DA Collier","year":"2021","unstructured":"Collier DA, Ferreira I, Kotagiri P, et al. Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2. Nature. 2021;596:417\u201322.","journal-title":"Nature"},{"key":"1443_CR3","doi-asserted-by":"publisher","first-page":"e002266","DOI":"10.1136\/jitc-2020-002266","volume":"9","author":"A Passaro","year":"2021","unstructured":"Passaro A, Bestvina C, Velez Velez M, Garassino MC, Garon E, Peters S. Severity of COVID-19 in patients with lung cancer: evidence and challenges. J Immunother Cancer. 2021;9:e002266.","journal-title":"J Immunother Cancer"},{"key":"1443_CR4","first-page":"401","volume":"123","author":"I Yakup","year":"2022","unstructured":"Yakup I, Eyyup C, Kubilay K, et al. Immunogenicity and safety of the CoronaVac vaccine in patients undergoing treatment for breast and lung cancer. Bratisl Med J Bratislavske Lekarske Listy. 2022;123:401\u20137.","journal-title":"Bratisl Med J Bratislavske Lekarske Listy"},{"key":"1443_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13578-021-00713-2","volume":"11","author":"C Zeng","year":"2021","unstructured":"Zeng C, Evans JP, Reisinger S, et al. Impaired neutralizing antibody response to COVID-19 mRNA vaccines in cancer patients. Cell Biosci. 2021;11:197.","journal-title":"Cell Biosci"},{"key":"1443_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.ccell.2021.12.014","volume":"40","author":"C Zeng","year":"2022","unstructured":"Zeng C, Evans JP, Chakravarthy K, et al. COVID-19 mRNA booster vaccines elicit strong protection against SARS-CoV-2 Omicron variant in patients with cancer. Cancer Cell. 2022;40:117\u20139.","journal-title":"Cancer Cell"},{"key":"1443_CR7","doi-asserted-by":"publisher","first-page":"e2381","DOI":"10.1002\/rmv.2381","volume":"32","author":"LB Shrestha","year":"2022","unstructured":"Shrestha LB, Foster C, Rawlinson W, Tedla N, Bull RA. Evolution of the SARS-CoV-2 omicron variants BA.1 to BA.5: implications for immune escape and transmission. Rev Med Virol. 2022;32:e2381.","journal-title":"Rev Med Virol"},{"key":"1443_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41421-022-00375-5","volume":"8","author":"X Yu","year":"2022","unstructured":"Yu X, Wei D, Xu W, et al. Reduced sensitivity of SARS-CoV-2 Omicron variant to antibody neutralization elicited by booster vaccination. Cell Discov. 2022;8:4.","journal-title":"Cell Discov"},{"key":"1443_CR9","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1016\/S0140-6736(20)32466-1","volume":"396","author":"MN Ramasamy","year":"2021","unstructured":"Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2\/3 trial. Lancet. 2021;396:1979\u201393.","journal-title":"Lancet"},{"key":"1443_CR10","doi-asserted-by":"publisher","first-page":"e0056121","DOI":"10.1128\/Spectrum.00561-21","volume":"9","author":"H Kawasuji","year":"2021","unstructured":"Kawasuji H, Morinaga Y, Tani H, et al. Age-dependent reduction in neutralization against alpha and beta variants of BNT162b2 SARS-CoV-2 vaccine-induced immunity. Microbiol Spectr. 2021;9:e0056121.","journal-title":"Microbiol Spectr"},{"key":"1443_CR11","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1038\/s41591-021-01542-z","volume":"27","author":"RT Shroff","year":"2021","unstructured":"Shroff RT, Chalasani P, Wei R, et al. Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors. Nat Med. 2021;27:2002\u201311.","journal-title":"Nat Med"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01443-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-023-01443-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-023-01443-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T12:06:38Z","timestamp":1683115598000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-023-01443-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,3]]},"references-count":11,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1443"],"URL":"https:\/\/doi.org\/10.1186\/s13045-023-01443-3","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,3]]},"assertion":[{"value":"3 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been approved by the Ethics Committee of the National Cancer Center\/National Clinical Research Center for Cancer\/Cancer Hospital, Peking Union Medical College and the Chinese Academy of Medical Sciences Permission (22\/363-3565) and Peking Union Medical College Hospital (I-22PJ354). All experiments were performed according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"47"}}